** Surgical device maker AxoGen's shares AXGN.O rise 2.6% to $18.5 premarket
** Co reports Q4 profit of 7 cents/share, beating analyst estimates of 3 cents/share, as per data compiled by LSEG
** Co posts Q4 revenue of $49.4 mln vs analyst est of $48.6 mln
** AXGN forecasts 2025 revenue growth of 15% to 17%
** Stock has risen 72% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。